CD19 and systemic lupus erythematosus: In 2018, a research team from Shanghai, China, registered the first clinical trial (NCT03030976) investigating CAR-T-cell therapy (anti-CD19 CAR-T cells®) for refractory systemic lupus erythematosus (SLE).